Synthesis of Glycopeptide-Based Cancer Antigen Vaccines
糖肽癌抗原疫苗的合成
基本信息
- 批准号:8878565
- 负责人:
- 金额:$ 42.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-05-01 至 2019-04-30
- 项目状态:已结题
- 来源:
- 关键词:Active ImmunotherapyAdjuvantAffinity ChromatographyAntibodiesAntibody ResponseAntigen PresentationAntigen-Presenting CellsAntigensB-LymphocytesBindingCD8B1 geneCancer VaccinesCarbohydratesCellsCeramidesChemicalsChimera organismCross PresentationCytolysisEffectivenessEngineeringEnhancing AntibodiesEnvironmentFc ReceptorFc domainFicollGenerationsGlycoconjugatesGlycolipidsGlycopeptidesHealthHumanImmuneImmune responseImmunizationImmunologyIndividualInterferonsKRN7000LigandsLipidsLiposomesMalignant NeoplasmsMediatingMucin-1 Staining MethodMusNeoplasm MetastasisOligosaccharidesOrganic ChemistryPeptidesProductionPropertyRecombinantsResearch PersonnelRhamnoseRoleSiteStructureSynthetic VaccinesT-LymphocyteTestingTrainingTumor AntibodiesTumor ImmunityTumor-Associated Carbohydrate AntigensUrsidae FamilyVaccine AdjuvantVaccine AntigenVaccinesWild Type MouseWorkXenobioticsbasecancer cellcancer recurrencecarbohydrate structurecytokineimprovedinterestkiller T cellmouse modelneoplastic cellresponsetumoruptakevaccine candidatevaccine developmentvaccine effectiveness
项目摘要
DESCRIPTION (provided by applicant): Tumor-associated carbohydrate antigens (TACAs) are saccharides and oligosaccharides which show highly restricted expression on cancer cells. Since TACAs are unique to cancer cells, there is a great interest in generating an active immune response against TACAs as a means of reducing cancer metastasis or recurrence. Two major challenges to using TACAs in active immunotherapy are their poor antigenicity and the inherent difficulty of synthesizing oligosaccharides and related glycoconjugates by chemical means. Past work demonstrated that liposomal vaccines with a TACA- bearing peptide can generate immune responses to TACAs. If the liposome contains a xenobiotic carbohydrate such as rhamnose, natural antibodies against the carbohydrate will greatly enhance the generation of an immune response, presumably through Fc mediated antigen uptake. The first specific aim of this proposal seeks to determine in more detail the mechanism of enhancement by studying purified human anti-rhamnose antibodies and their role in antigen uptake in wild type and Fc humanized mice. The second specific aim will determine if a specific Fc region can serve as a more generally effective targeting ligand than rhamnose for this vaccine. The most effective vaccine formulation will be tested in humanized mice to better predict its efficacy in humans. Stimulation of invariant natural killer T cells by certain ceramides can serve as a vaccine adjuvant. The third specific aim involves synthesis of rhamnose-modified ceramides and determining if they can serve as improved vaccine adjuvants through binding to CD1d in addition to providing a recognition site for natural antibodies. This proposal takes advantage of a
collaborative interaction between researchers trained in organic chemistry and immunology so that the structure and antigenicity of all vaccines will be well characterized in wild type mice an in mice bearing humanized immune cells.
描述(由申请人提供):肿瘤相关碳水化合物抗原(TACA)是在癌细胞上表现出高度受限表达的糖类和寡糖,由于TACA是癌细胞所独有的,因此人们对产生针对TACA的主动免疫反应非常感兴趣。在主动免疫治疗中使用 TACA 的两个主要挑战是其抗原性差以及合成寡糖和相关的固有困难。过去的工作表明,带有 TACA 肽的脂质体疫苗可以产生针对 TACA 的免疫反应,如果脂质体含有异生碳水化合物(例如鼠李糖),针对碳水化合物的天然抗体将大大增强免疫反应的产生。大概是通过 Fc 介导的抗原摄取,该提案的第一个具体目标是通过研究纯化的人抗鼠李糖抗体及其在野生型和 Fc 中抗原摄取中的作用来更详细地确定增强机制。第二个具体目标是确定特定的 Fc 区域是否可以作为该疫苗比鼠李糖更有效的靶向配体,并将在人源化小鼠中进行测试,以更好地预测其对人类的刺激效果。第三个具体目标是合成鼠李糖修饰的神经酰胺,并确定它们是否可以通过与 CD1d 结合来作为改进的疫苗佐剂。除了提供天然抗体的识别位点之外,该提案还利用了
接受过有机化学和免疫学培训的研究人员之间的协作互动,以便在野生型小鼠和携带人源化免疫细胞的小鼠中很好地表征所有疫苗的结构和抗原性。
项目成果
期刊论文数量(12)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Mixed-phase synthesis of glycopeptides using a N-peptidyl-2,4-dinitrobenzenesulfonamide-thioacid ligation strategy.
- DOI:10.1021/ol202163e
- 发表时间:2011-10-07
- 期刊:
- 影响因子:5.2
- 作者:Karmakar P;Talan RS;Sucheck SJ
- 通讯作者:Sucheck SJ
Synthesis of β-Glycosyl Amides from N-Glycosyl Dinitrobenzenesulfonamides.
- DOI:10.1080/07328303.2012.663431
- 发表时间:2012-01-01
- 期刊:
- 影响因子:1
- 作者:Gaitonde V;Sucheck SJ
- 通讯作者:Sucheck SJ
Development of a Bioconjugate Platform for Modifying the Immune Response of Autoreactive Cytotoxic T Lymphocytes Involved in Type 1 Diabetes.
开发用于改变 1 型糖尿病相关自身反应性细胞毒性 T 淋巴细胞免疫反应的生物共轭平台。
- DOI:10.1021/acs.bioconjchem.9b00332
- 发表时间:2019
- 期刊:
- 影响因子:4.7
- 作者:Nandedkar-Kulkarni,Neha;Vartak,AbhishekR;Sucheck,StevenJ;Wall,KatherineA;Quinn,Anthony;Morran,MichaelP;McInerney,MarciaF
- 通讯作者:McInerney,MarciaF
Augmenting Vaccine Immunogenicity through the Use of Natural Human Anti-rhamnose Antibodies.
- DOI:10.1021/acschembio.8b00312
- 发表时间:2018-08-17
- 期刊:
- 影响因子:4
- 作者:Hossain MK;Vartak A;Karmakar P;Sucheck SJ;Wall KA
- 通讯作者:Wall KA
Oligosaccharide synthesis on soluble high-molecular weight pHEMA using a photo-cleavable linker.
使用光裂解接头在可溶性高分子量 pHEMA 上合成寡糖。
- DOI:10.1039/c8ra08252a
- 发表时间:2018
- 期刊:
- 影响因子:3.9
- 作者:Vartak,Abhishek;Thanna,Sandeep;Meyer,Kyle;Dermanelian,Miranda;Sucheck,StevenJ
- 通讯作者:Sucheck,StevenJ
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KATHERINE A WALL其他文献
KATHERINE A WALL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KATHERINE A WALL', 18)}}的其他基金
相似国自然基金
肿瘤微环境多层次调控的功能化纳米佐剂用于增强膀胱癌放疗疗效的机制研究
- 批准号:82303571
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
靶向FPPS的双磷酸疫苗佐剂的开发
- 批准号:82341040
- 批准年份:2023
- 资助金额:100 万元
- 项目类别:专项基金项目
双重生物响应性自佐剂聚多肽载体构建高效mRNA癌症疫苗
- 批准号:52373299
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
新型免疫调节复合佐剂的机制研究及在疫苗开发中的应用
- 批准号:82341039
- 批准年份:2023
- 资助金额:95 万元
- 项目类别:专项基金项目
皮内接种抗原佐剂复合疫苗跨器官诱导呼吸道黏膜免疫反应
- 批准号:82341042
- 批准年份:2023
- 资助金额:100 万元
- 项目类别:专项基金项目
相似海外基金
Host proteins that interact with the BCG cell envelope
与 BCG 细胞包膜相互作用的宿主蛋白
- 批准号:
10408860 - 财政年份:2021
- 资助金额:
$ 42.08万 - 项目类别:
Host proteins that interact with the BCG cell envelope
与 BCG 细胞包膜相互作用的宿主蛋白
- 批准号:
10288316 - 财政年份:2021
- 资助金额:
$ 42.08万 - 项目类别:
Exploiting cross-reactive, conserved epitopes in Plasmodium vivax to develop a vaccine against falciparum placental malaria.
利用间日疟原虫中的交叉反应性保守表位开发针对恶性胎盘疟疾的疫苗。
- 批准号:
10583568 - 财政年份:2020
- 资助金额:
$ 42.08万 - 项目类别:
Production and Characterization of Human Immunoglobulin Producing Goats for Diagnostic Reagents and Therapeutics
用于诊断试剂和治疗的人免疫球蛋白生产山羊的生产和表征
- 批准号:
9916705 - 财政年份:2018
- 资助金额:
$ 42.08万 - 项目类别:
The Molecular Pathology and Etiology of Nephrogenic Systemic Fibrosis
肾源性系统纤维化的分子病理学和病因学
- 批准号:
9384115 - 财政年份:2017
- 资助金额:
$ 42.08万 - 项目类别: